GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma

2023495 citationsJournal Article

Authors

Francesca Del Bufalo · Mahindra and Mahindra Limited (India)

Biagio De Angelis · Mahindra and Mahindra Limited (India)

Ignazio Caruana · Mahindra and Mahindra Limited (India)

Giada Del Baldo · Mahindra and Mahindra Limited (India)

Maria Antonietta De Ioris · Mahindra and Mahindra Limited (India)

Annalisa Serra · Mahindra and Mahindra Limited (India)

Angela Mastronuzzi

Abstract

The use of GD2-CART01 was feasible and safe in treating high-risk neuroblastoma. Treatment-related toxic effects developed, and the activation of the suicide gene controlled side effects. GD2-CART01 may have a sustained antitumor effect. (Funded by the Italian Medicines Agency and others; ClinicalTrials.gov number, NCT03373097.).

Topics & Keywords

CAR-T cell therapy research Neuroblastoma Research and Treatments Virus-based gene therapy research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 388, Issue 14, pp. 1284-1295

DOI: 10.1056/nejmoa2210859

Field-Weighted Citation Impact: 113.20